Key Insights from the Registry Can Help
Policymakers and Health Care Professionals Formulate Strategies to
Manage Liver Cancer Patients
National Cancer Centre Singapore (NCCS), Singapore Clinical
Research Institute (SCRI) and IMS Health (NYSE:IMS) will
collaborate to develop its first Liver Cancer or Hepatocellular
Carcinoma (HCC) Registry in Asia through the Asian HCC Physician
Network.
The non-identified data from this Registry can help policymakers
and health care professionals formulate strategies to manage liver
cancer patients.
This collaboration is led by Prof. Pierce Chow, Senior
Consultant Surgeon at NCCS and Chairman of the Physician
Network.
“HCC is a leading cause of cancer-related death worldwide, and
the burden of this devastating cancer is expected to increase
further in coming years. The collection and analysis of
epidemiologic HCC data will play a critical role in guiding future
disease prevention strategies and optimizing patient management,”
said Associate Prof. Teoh Yee Leong, Public Health Physician and
CEO of Singapore Clinical Research Institute.
Previous epidemiologic studies have highlighted striking global
variations in the incidence of HCC, which is particularly high in
much of East Asia and sub-Saharan Africa, and lower, but on the
rise in North America and most of Europe. Although previous studies
have contributed considerably to the knowledge of HCC epidemiology,
there are limitations associated with the currently available data.
This arose from studies performed at different times in the past,
using varying methodologies, and with diverse patient
populations.
“This information gap prevents estimation of current and future
disease burden and impedes efforts to lobby health policymakers to
improve public health measures, as given the size of Asia Pacific
populations, prevention rather than treatment of non-communicable
diseases remains key,” added Prof. Teoh.
NCCS Director Prof. Soo Khee Chee said, “This public-private
registry is timely and leverages on the Asia-Pacific HCC network
that we have developed over the last two decades. The aim of the
registry is aligned with the mission of NCCS and we look forward to
better prevention and treatment strategies for HCC in Asia
Pacific.”
NCCS Prof. Pierce Chow said a fresh approach to the study of the
epidemiology of HCC is required if HCC disease prevention and
treatment strategies are to be adequately directed and supported in
coming years.
”Real world data on the presentation, clinical trajectory and
management of HCC in the Asia-Pacific must be prospectively
collected on the ground if we were to improve public health
measures and develop effective public health strategies,” explained
Prof. Chow.
According to the Vice President IMS Health Asia Pte Ltd., Mr.
Amit Backliwal, "Cancer in Asia is fast becoming a huge burden of
disease and cost of care is now spiraling. With access to
non-identified, longitudinal patient data, IMS will be able to help
healthcare stakeholders in more informed decision making and drive
better health outcomes overall through proprietary analytics and
technology solutions."
This public-private collaboration will also provide invaluable
information to the pharmaceutical industry, governmental and
insurance payers and physicians, delivering a complete longitudinal
picture of the disease using a combination of retrospective and
prospective clinical, associated health costs and patient reported
outcomes data. The Registry will help to answer important questions
such as different treatment patterns / strategies; health care
resource use and costs of treatments; as well as first-hand
insights to patients’ perspectives on their treatments.
Using this real world data, government planning agencies and
pharmaceutical companies can benefit through bespoke analytics to
establish their clinical development and product strategies. Payers
will have a good understanding of the disease burden and budget
impact to better craft the public health policies. Physicians will
be able to use this data to better optimize care pathways enhancing
treatment outcomes for HCC patients.
About National Cancer Centre Singapore
National Cancer Centre Singapore (NCCS) provides a holistic and
multi-disciplinary approach to cancer treatment and patient care.
We treat almost 70 per cent of the public sector oncology cases,
and they are benefiting from the sub-specialization of our clinical
oncologists. NCCS is also accredited by the US-based Joint
Commission International for its quality patient care and
safety.
To deliver among the best in cancer treatment and care, our
clinicians work closely with our scientists who conduct robust
cutting-edge clinical and translational research programs which are
internationally recognized. NCCS strives to be a global leading
cancer centre, and shares its expertise and knowledge by offering
training to local and overseas medical professionals.
www.nccs.com.sg
About Singapore Clinical Research Institute
Singapore Clinical Research Institute (SCRI) is a National
Academic Research Organization dedicated to enhance the standards
of human clinical research. Its mission is to spearhead and develop
core capabilities, infrastructure and scientific leadership for
clinical research in Singapore. SCRI is a national clinical trials
coordination centre that works with National Medical Research
Council (NMRC) to assist the Ministry of Health in implementing
clinical trials policy and strategic initiatives to support and
develop clinical research competencies locally.
In driving towards its vision, SCRI collaborates with clinicians
to enhance Singapore’s clinical research and strengthen its
expertise in executing multi-site, multi-national studies and the
development of regional clinical research networks.
SCRI is a wholly-owned subsidiary of MOH Holdings.
http://www.scri.edu.sg
About IMS Health
IMS Health is a leading global information and technology
services company providing clients in the healthcare industry with
end-to-end solutions to measure and improve their performance. Our
7,500 services experts connect configurable SaaS applications to
10+ petabytes of complex healthcare data in the IMS One™ cloud
platform, delivering unique insights into diseases, treatments,
costs and outcomes. The company’s 15,000 employees blend global
consistency and local market knowledge across 100 countries to help
clients run their operations more efficiently. Customers include
pharmaceutical, consumer health and medical device manufacturers
and distributors, providers, payers, government agencies,
policymakers, researchers and the financial community.
As a global leader in protecting individual patient privacy, IMS
Health uses anonymous healthcare data to deliver critical,
real-world disease and treatment insights. These insights help
biotech and pharmaceutical companies, medical researchers,
government agencies, payers and other healthcare stakeholders to
identify unmet treatment needs and understand the effectiveness and
value of pharmaceutical products in improving overall health
outcomes. Additional information is available at
www.imshealth.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160201006385/en/
Media:IMS HealthTor Constantino,
1-484-567-6732tconstantino@us.imshealth.comorNational Cancer Centre
SingaporeEdwin Yong, +65 6236 9465Executive, Corporate
Communicationsedwin.yong.c.y@nccs.com.sgorSingapore Clinical
Research InstituteAlexa Shee, +65
6508-8334alexa.shee@scri.edu.sg
IMS HEALTH HOLDINGS, INC. (NYSE:IMS)
Historical Stock Chart
From Jun 2024 to Jul 2024
IMS HEALTH HOLDINGS, INC. (NYSE:IMS)
Historical Stock Chart
From Jul 2023 to Jul 2024